Copyright
©The Author(s) 2015.
World J Gastroenterol. Jun 21, 2015; 21(23): 7233-7241
Published online Jun 21, 2015. doi: 10.3748/wjg.v21.i23.7233
Published online Jun 21, 2015. doi: 10.3748/wjg.v21.i23.7233
Inclusion and exclusion criteria |
Inclusion criteria (all of the following) |
Small bowel plus colonic Crohn's disease |
Non-stricturing, non-penetrating phenotype |
Corticosteroid-free remission (Harvey-Bradshaw Index < 5) |
Follow-up ≥ 1 yr |
Age ≥ 18 yr |
Exclusion criteria (any of the following) |
Pregnancy |
Intestinal obstruction/obstructive symptoms |
Intestinal surgery |
Non-steroidal anti-inflammatory drug use within 4 wk of enrolment |
Result | Diagnosis | Follow-up | Reference |
Hemoglobin (g/dL) | 13.2 ± 2.8 | 14.2 ± 1.4 | 12.0-18.0 |
Leucocytes (103/μL) | 10.100 ± 3.200 | 7.800 ± 2.800 | 4.8-10.8 |
Platelets (103/μL) | 363 ± 194 | 265 ± 124 | 150-350 |
Erythrocyte sedimentation rate (mm/h) | 28.6 ± 23.8 | 12.3 ± 8.3 | 0-14 |
C-reactive protein (mg/L) | 42.6 ± 36.4 | 17.2 ± 17.0 | < 2.9 |
Ferritin (ng/mL) | 120 ± 112 | 74 ± 49 | 26-388 |
Albumin (ng/mL) | 4.1 ± 0.6 | 3.9 ± 0.3 | 3.1-17.5 |
Patient | Age (yr) | Sex | Follow-up (mo) | Therapy | SBCE LS | Index colonoscopy colon findings | PCC2 LS | PCC2 colon findings |
1 | 21 | Male | 48 | Azathioprine 2.5 mg/kg per day | 2980 | Extensive ulcers and erythema in entire colon | 1068 | Extensive ulcers in entire colon |
2 | 21 | Female | 63 | Azathioprine 2.5 mg/kg per day Adalimumab 40 mg eow | 1440 | Extensive ulcers and erythema in entire colon | 2336 | No lesions |
3 | 26 | Male | 57 | Azathioprine 2.5 mg/kg per day Adalimumab 40 mg eow | 1350 | Aphtoid ulcers and erythema in the sigmoid | 562 | No lesions |
4 | 48 | Male | 33 | Azathioprine 2.5 mg/kg per day | 1240 | Aphtoid ulcers and erythema in the cecum | 5392 | Extensive ulcers in the ascending and transverse colon |
5 | 24 | Male | 39 | Mesalazine 3 g/d | 1104 | Aphtoid ulcers in the cecum | 1518 | Aphtoid ulcers in the cecum |
6 | 27 | Female | 14 | Azathioprine 2.5 mg/kg per day | 900 | Extensive ulcers and erythema proximal to the splenic flexure | 0 | Ulcers in the transverse colon |
7 | 18 | Male | 14 | Azathioprine 2.5 mg/kg per day | 1690 | Extensive ulcers and erythema in entire colon | 2336 | Ulcers in the cecum, ascending, transverse and descending colon |
8 | 35 | Female | 22 | Azathioprine 2.5 mg/kg per day | 314 | Aphtoid ulcers and erythema in the cecum | 5392 | No lesions |
9 | 32 | Male | 22 | Mesalazine 3 g/d | 458 | Extensive ulcers and erythema in entire colon | 0 | No lesions |
10 | 46 | Female | 49 | Azathioprine 2.5 mg/kg per day | 393 | Extensive ulcers and erythema proximal to the splenic flexure | 0 | No lesions |
11 | 50 | Female | 65 | Azathioprine 2.5 mg/kg per day | 225 | Ulcers in the sigmoid | 8 | Ulcerative lesions in the splenic flexure; |
12 | 39 | Male | 62 | Mesalazine 3 g/d | 168 | Aphtoid ulcers in the cecum and ascending colon | 0 | No lesions |
- Citation: Boal Carvalho P, Rosa B, Dias de Castro F, Moreira MJ, Cotter J. PillCam COLON 2© in Crohn’s disease: A new concept of pan-enteric mucosal healing assessment. World J Gastroenterol 2015; 21(23): 7233-7241
- URL: https://www.wjgnet.com/1007-9327/full/v21/i23/7233.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i23.7233